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abstract
The pathogenesis of Alzheimer’s disease (AD) has been mostly linked to aberrant amyloid beta (Aβ) and tau pro-
teins metabolism, disturbed lipid/cholesterol homeostasis, and progressive neuroinflammation. Liver X receptors 
(LXR) are ligand-activated transcription factors, best known as the key regulators of cholesterol metabolism and 
transport. In addition, LXR signaling has been shown to have significant anti-inflammatory properties. In this brief 
review, we focus on the outcome of studies implicating LXR in the pathogenesis, modulation, and therapy of AD.
1. introduction
Alzheimer’s disease (AD) accounts for about 
55-70% of adult-onset dementia in the 
industrialized world [1] and is the fifth leading 
cause of death in the USA in people older 
than 65 [2]. A number of risk factors for AD 
have been identified, such as hypertension, 
hyperlipidemia, cardiovascular disease, 
diabetes mellitus, and obesity [3]. However, 
AD etiopathogenesis still remains poorly 
understood. Relatively rare familial forms of 
AD have been linked to mutations in amyloid 
precursor protein (APP), presenilin 1 (PSEN1) or 
presenilin 2 (PSEN2) genes, while genetic risk 
factors for the more prevalent sporadic AD are 
much less clear [4,5]. Several key components 
of AD pathogenesis have been well identified 
and characterized, including aberrant amyloid-
beta peptide (Aβ) [6] and tau metabolism 
[7], disturbed lipid/cholesterol homeostasis 
[8], and progressive neuroinflammation [9]. 
However, despite decades of intensive research 
on many aspects of the disease, AD remains an 
unpreventable and life-threatening condition 
with no effective treatments for either curing it 
or slowing its progression [10]. 
Liver-X receptors (LXR) are members of the 
large superfamily of nuclear receptors (NR) 
that share similar functions and conserved 
molecular structure [11]. These proteins, 
classified as transcription factors, directly 
interact with the regulatory DNA sequences 
and upon activation by binding of agonists 
to their ligand binding domains, modulate 
transcription of the target genes. The two LXR 
isoforms, LXRα and LXRβ (known also as NR1H3 
and NR1H2, respectively) were discovered 
between 1994-1995 based on the sequence 
homology with other NR [12,13]. LXRα, initially 
isolated from a rat liver cDNA library as a novel 
NR with unknown physiological ligands (hence 
the name “liver-X receptor”) is found at high 
levels in cholesterol-metabolizing tissues, 
while LXRβ is ubiquitously expressed. Natural 
(endogenous) ligands for both LXR isoforms are 
oxysterols, the most potent of which are 24(S)-
hydroxycholesterol, 27-hydroxycholesterol, 
22(R)-hydroxycholesterol, and 24(S),25-
epoxycholesterol [12]. Many of the LXR 
target genes, including ATP-binding cassette 
transporters A1 (ABCA1) and G1 (ABCG1), 
apolipoprotein E (apoE), apolipoprotein M 
(apoM), phospholipid transfer protein (PLTP) 
and several other proteins, have been shown 
to be centrally involved in cholesterol transport 
and metabolism in various tissues and cell 
types. Hence, LXRs are best known as the 
master transcriptional regulators of cellular 
and whole-body cholesterol/lipid homeostasis 
[14-17]. In addition, LXRs have been also 
implicated in the regulation of immune response 
[18] and carbohydrate metabolism [19].
Due to the ability to integrate metabolic and 
immune signaling, LXR have been recognised 
as attractive therapeutic targets for chronic 
metabolic and/or inflammatory diseases as 
diverse as atherosclerosis, dyslipidaemia, 
and cancer [20]. There is increasing evidence 
linking LXR to pathogenesis and modulation 
of neurodegenerative disorders, including 
AD. Several LXR-controlled genes have been 
reported to be dysregulated in the brains of 
AD patients [21-24] and overexpression or 
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deletion of some LXR target genes in animal 
models of AD has been shown to alter AD-
related pathology [25-27]. Here we briefl y 
outline genetic and pharmacological studies 
linking LXR to AD, and delineate LXR-regulated 
pathways that could possibly modulate the 
outcome of this devastating disease (Figure 1). 
 2.  genetic evidence 
imPlicating lXrs in 
neurodegeneration and 
Pathogenesis of ad
 2.1. LXR knockout mice
The fi rst evidence for the roles of LXR in 
neurodegeneration came from a study 
examining the neurological phenotype of mice 
with inactivated genes of both LXR isoforms 
[28]. Brains of these animals display several 
severe abnormalities including excessive lipid 
deposits, morphological changes of blood 
vessels and choroid plexus, proliferation of 
astrocytes, loss of neurons, and disorganisation 
of myelin sheets. Furthermore, mice with 
selective inactivation of the LXRβ isoform 
were shown to suff er from impaired motor 
coordination [29] and reduced number of 
neurons in the superfi cial cortical layers 
[30]. Zelcer et al. [31] reported that loss of 
either LXRα or LXRβ in a mouse model of AD 
aggravates AD-related pathology, i.e. increases 
Aβ plaque load in the brain tissue, while 
Terwell et al. [32] demonstrated that lack of 
LXRα impairs Aβ phagocytosis in AD mice. 
Deleterious eff ects of LXR inactivation have 
been shown also in mouse models of Niemann-
Pick type C disease (NPC), a monogenic 
neurodegenerative disorder associated with 
intracellular lipid/cholesterol accumulation 
[33]. Taken together, LXR-knockout studies 
clearly show that LXR have important roles in 
brain physiology and suggest that impaired 
functions of these receptors could be initiating 
and/or contributing factors in the progression 
of neurodegenerative processes.
 2.2.  Human genetic association 
studies 
Roles of mutations and polymorphisms in 
genes for LXRs in the etiopathogenesis of 
human diseases corresponding to phenotypes 
observed in LXR-knockout mice, remain largely 
unexplored. The human gene encoding LXRα 
(LXRα, NR1H3) is located on chromosome 
11, while the human gene encoding LXRβ 
(LXRβ, NR1H2) is located on chromosome 19. 
According to data available at the National 
Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov/), both genes contain 
a number of single nucleotide polymorphisms 
(SNPs): 234 (41 in the coding region) and 130 
(28 in the coding region) SNPs have been 
identifi ed in LXRα and LXRβ genes, respectively. 
Although many of these SNPs are located 
within the regulatory gene regions or represent 
missense variants, no data are currently 
available on their functional relevance. So 
far, only polymorphisms in the LXRβ gene 
have been investigated for association with 
sporadic AD, while no such data is available 
for the LXRα gene. Adighibe et al. conducted 
a family-based association study analysing 
LXRβ polymorphisms rs1802589, rs2695121, 
rs1052533, and rs1405655 in a total of 1327 
subjects (including late-onset AD patients and 
their unaff ected siblings) originating from 458 
nuclear families [34]. The results suggested 
that genetic variability at the LXRβ locus may 
be a risk factor for late onset AD in the USA 
population. A subsequent case-control study 
in 414 AD patients and 447 control subjects 
Figure 1.  LXRs signaling targets brain cholesterol homeostasis, amyloid-β (Aβ) pathology and neuroinfl ammation 
in AD mice.  Activation of the DNA-bound LXR/RXR complex by natural or synthetic agonists of either 
partner alters transcriptional activity of target genes. Induction of cholesterol-related genes normalises 
brain cholesterol homeostasis and decreases brain Aβ load, while suppression of pro-infl ammatory 
genes reduces brain infl ammation. The behavioural phenotype improves as the consequence of these 
biochemical changes. 
 






of Spanish origin, however, found no evidence 
for the association of rs2695121, rs1052533 
and rs1405655 genotypes or haplotypes with 
the sporadic AD [35]. No association between 
rs1405655 and AD was found also in a Swedish 
population, although this study included only 
86 AD patients and might have lacked statistical 
power to detect minor gene effects [36]. Two 
additional studies in a Spanish population 
investigated possible interactions of the LXRβ 
gene and other genes in determining the 
risk for sporadic AD. The first study, including 
266 AD patients and 273 healthy controls, 
examined polymorphism rs1052533 in the 
LXRβ gene and polymorphism rs2569190 in 
the gene encoding CD14, a surface receptor 
implicated in inflammatory response [37]. The 
results suggested that the two investigated 
polymorphisms might have combined effects 
on the susceptibility to sporadic AD. The 
second study, involving 414 AD patients and 
442 healthy subjects, examined three SNPs 
(rs2695121, rs1052533 and rs1405655) in the 
LXRβ gene and one SNP (rs2071746) in the 
gene encoding heme oxygenase-1 (HO-1), 
an enzyme that stimulates oxidation of glial 
cholesterol to oxysterols [38]. The concomitant 
presence of the HO-1 risk genotype and any of 
the LXRβ risk genotypes was associated with 
a significantly increased risk of developing 
AD. Further association as well as functional 
studies are required to elucidate possible roles 
of LXRα and LXRβ gene polymorphisms in the 
etiopathogenesis of sporadic AD.
3.  Pharmacological studies 
linKing lXrs to modulation 
of ad Pathology
LXRs are physiologically activated by binding 
of certain oxidized derivatives of cholesterol 
(oxysterols) to their ligand-binding domain [12]. 
Some of the most potent endogenous agonists 
of LXRs include 22(R)-hydroxycholesterol, 
24(S)-hydroxycholesterol (brain-specific 
cholesterol metabolite), 27-hydroxycholesterol, 
and 24(S),25-epoxycholesterol. In addition, a 
number of nutrition-derived oxysterols as well 
as synthetic compounds, the most common 
being T0901317 (TO90) and GW3965 (GW), 
have been recognised as potent ligands of LXRs 
[39]. In vitro and in vivo studies performed over 
the last decade have shown that LXR activation 
by either natural or synthetic ligands exerts 
marked effects on gene expression in brain 
cells. Furthermore, evidence has been gathered 
for the beneficial effects of LXR agonists on 
cerebral cholesterol homeostasis, Aβ levels, 
neuroinflammation, and, finally, behavioural 
performance in AD model mice.
3.1.  Effects of LXR agonists on 
cholesterol homeostasis
Multiple lines of evidence suggest that 
alterations in cholesterol homeostasis are 
closely associated with the pathogenesis of 
AD [8,40-42]. Natural and synthetic agonists 
of LXRs were shown to up-regulate expression 
and activity of cholesterol-related genes, such 
as ABCA1, ABCG1, and apoE, in various types 
of brain cells, including neurones, astrocytes, 
microglia, oligodendrocytes, and brain 
capillary endothelial cells [43-51]. Concurrently, 
in vivo studies demonstrated increased levels of 
ABCA1, ABCG1, apoE, and Srebp1 in brains of 
mice treated with synthetic LXR agonists TO90 
and GW [31,43,46,52,53]. In addition, Eckert 
et al. (2007) demonstrated that TO90-mediated 
induction of ABCA1, ABCG1 and apoE was 
accompanied by the decrease of cholesterol 
levels in cortical synaptosomal plasma 
membranes [53]. Furthermore, administration 
of TO90 to rats upregulated apoE and total 
cholesterol levels in cerebrospinal fluid (CSF), 
suggesting that LXR activation stimulates 
elimination of brain cholesterol via secretion 
of apoE-lipidated particles into the CSF [54]. 
Similarly to results on wild-type animals, 
synthetic LXR agonists elevated levels of 
ABCA1, ABCG1, apoE and Srebp1 also in brains 
of different animal models of AD [32,46,55-61].
In addition, TO90 decreased membrane 
cholesterol levels [60] and increased levels of 
cholesterol precursors [61] in the brains of AD 
mice. Increased brain cholesterol excretion 
upon application of TO90 was demonstrated 
also in NPC mice [62]. Taken together, these 
studies suggest that brain-penetrable LXR 
agonists do regulate brain expression of 
genes related to cholesterol homeostasis and 
enhance brain cholesterol turnover under both 
physiological as well as pathological conditions.
3.2.  Effects of LXR agonists on Ab 
levels 
Aβ peptide, the main constituent of senile 
plaques found in brain parenchyma of AD 
patients, is believed to play central role in the 
pathogenesis as well as therapy of AD [6,63]. 
Aβ is formed during amyloidogenic processing 
of amyloid precursor protein (APP), by the 
successive action of β-secretase (BACE1) and 
presenilin (PSEN)-containing protease complex 
γ-secretase. APP can be processed also in a non-
amyloidogenic pathway involving α-secretase 
in the first proteolytic step. Studies in different 
murine models of amyloidogenesis (summarised 
in Table 1) have consistently reported that 
synthetic LXR agonists decrease brain Aβ 
burden [32,56-60,64,65], the only exception 
being a study performed in aged APPSLxPS1mut 
mice [61]. A decrease in Aβ levels was observed 
also in brains of wild-type mice [52] and rats 
[54] treated with TO90 for only 7 and 6 days, 
respectively. The outcome of most in vitro studies 
in neuronal and non-neuronal cellular models 
also demonstrated reducing effects of LXR 
agonists on Aβ levels [45,48,49,52,55,60,66]. One 
study reported a modest increase rather than 
decrease in the secretion of Aβ peptides [44]; the 
reasons for the discrepancy could be related to 
the experimental set-up and/or use of murine 
wild type APP (instead of the human Swedish 
mutant APP) as the source of Aβ peptides. A 
growing body of evidence suggests that the 
regulation of APP sorting/processing pathways 
is linked to cellular cholesterol levels and/or 
distribution (for review see [8,68]). Mechanisms 
by which LXRs regulate APP metabolism remain 
somewhat controversial, with studies reporting 
both cholesterol efflux-dependent as well as 
-independent effects of LXR agonists on Aβ 
levels [52,55,67]. Furthermore, some studies 
suggest that LXR agonists shift APP processing 
from β- to α-secretase cleavage influencing 
thus Aβ generation [49,60,64,69], while others 
argue that LXR agonists increase Aβ clearance 
or degradation rather than its production 
[32,57,58,70]. Recent in vivo data obtained using 
different doses of LXR agonist GW [59] along 
with our in vitro results [71] are indicative of a 
dose-effect of LXR agonists on APP processing, 
with only higher concentrations being able to 
decrease Aβ generation. 
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3.3.  Effects of LXR agonists on 
neuroinflammation
Ample evidence suggests that brain 
inflammation plays an important role in 
the pathogenesis of AD (for reviews see 
[72-74]). A number of inflammatory markers 
have been associated with AD, including 
the accumulation of activated microglia and 
elevation of inflammatory mediators such 
as inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2). LXRs were shown 
to regulate inflammatory gene expression 
in several tissues and cell types through 
the unique mechanism of transrepression 
[18,75,76]. In vitro studies have demonstrated 
that LXR agonists inhibit lipopolysaccharide 
(LPS)-, IFN-g-, or Aβ-induced inflammatory 
responses in primary microglia and 
astrocytes by reducing nitric oxide release 
and expression of various proinflammatory 
molecules including iNOS, COX-2, tumor 
necrosis factor-alpha (TNF-α), IL-1, IL-
6, interferon-beta, interferon regulatory 
factor-1, monocyte chemoattractant 
protein-1 (MCP-1) and others [31,56,65,77-80].
In addition, treatment of immortalised 
murine microglial cells with the synthetic 
LXR agonist GW was shown to reverse LPS-
induced inhibition of Aβ phagocytosis [31]. In 
vivo studies demonstrated that LXR agonists 
GW or TO90 reduce the neuroinflammatory 
response in experimental stroke [81], NPC 
mice [62], and in two lines of AD mice, i.e. 
APP23 [56] and APP/PS1 [65]. In addition, 
administration of TO90 to APP/PS1 mice 
significantly decreased microglial activation 
[65]. Both in vitro and in vivo data suggested 
that LXR agonists suppress the production 
of proinflammatory molecules in brain cells 
by inhibiting nuclear factor-kappa B (NF-kB) 
DNA-binding activity [65,79]. Collectively, 
these results indicate that LXR agonists could 
alleviate AD pathology by acting on the brain 
inflammatory response.
3.4.  Effects of LXR agonists on 
cognitive functions in AD mice
Memory loss is the earliest and the most 
common clinical manifestation of AD [82]. Mice 
overexpressing mutant APP and/or presenilins 
develop, along with AD-like neuropathology, 
also age-related memory deficits [83]. Different 
studies have shown that administration of 
synthetic LXR agonists restores behavioural 
phenotype in these animals. In particular, 
short-term administration of TO90 or GW (7 
or 6 days, respectively) [57,58] to Tg2576 mice 
restored contextual memory, as demonstrated 
by improved performance in contextual 
fear conditioning task. Long-term (8 weeks) 
treatment of APP/PS1 mice with GW completely 
restored object recognition memory and 
improved performance in Morris water maze 
tasks [59]. Long-term (6-9 weeks) application 
of TO90 restored object recognition and object 
location memory also in aged APPSLxPS1 mice 














behavior year of publication
APP23 11 weeks 6 days TO90 50 ↓ Aβ40, Aβ42 
not assessed
2005 [55]
APP23 6 months 4 weeks TO90 20 ↓ insoluble Aβ
not assessed
2007 [56]
Tg2576 5 months 7 days TO90 30 or 50 ↓ Aβ42 in hippocampus
improvement in contextual fear 
conditioning task 2007 [57]
Tg2576 5 months 6 days GW 50 not assessed
improvement in contextual fear 
conditioning task 2008 [58]
Tg2576 12 months 4 months GW 33 ↓ Aβ40, Aβ42
↓ Aβ plaque load
not assessed
2008 [58]
APP/PS1 8 months 8 weeks GW 2.5 or 33
a trend toward  reduced 
amyloid  load
improvements in object recognition 
and Morris  water maze tasks 2010 [59]
APP23 13 months 7 weeks TO90 50 ↓ Aβ in ISF
slight improvement in spatial learning 
in Morris water maze 2011 [32]
APP/PS1 8 months 12 days TO90 30
↓ Aβ40, Aβ42





21 months 6-9 weeks TO90 30 no effect on Aβ plaque load
improvement in object 
location and recognition tasks 2011 [61]
APP/PS1 6 months 30 days TO90 30
↓ Aβ42
↓ Aβ plaque area
improvement in Morris water maze 
performance 2012 [65]
Table 1.  Effects of synthetic LXR agonists on brain Aβ levels and behavior in mouse models of AD.
APP23 - mouse expressing human APP751 isoform containing the Swedish (K670N/M671C) familial AD mutation; Tg2576 - mouse expressing human APP695 isoform containing 
the Swedish (K670N/M671C) familial AD mutation; APP/PS1 - mouse coexpressing a chimeric human/mouse APP650 isoform containing the Swedish (K670N/M671C) familial AD 
mutation and the human PS1 gene deleted for exon 9; APPSLxPS1mut - mouse coexpressing human APP gene carrying the Swedish/London familial AD mutations and mutant PS1 
(M146L); TO90 - TO901317; GW - GW3965.
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aged APP23 mice [32]. Improvement in Morris 
water maze tasks was obtained also in APP/PS1 
mice treated for 30 days with TO90 [65]. TO90 
administration was further shown to reduce 
memory deficits caused by high-fat diet in 
APP23 mice [70]. 
4.  moving of lXr agonists to 
clinical Practice
In spite of favourable effects demonstrated 
in AD mice (summarised in Figure 1), moving 
of LXR agonists to clinical practice has been 
hampered owning to adverse side effects, 
the most serious being hepatic steatosis 
and increased production of atherogenic 
triacylglycerol-rich VLDL particles [84]. LXRs 
form permissive heterodimers with retinoid 
X receptors (RXRs), the receptors of 9-cis-
retinoid acid [85]. Binding of agonists to either 
member of the LXR/RXR complex facilitates 
exchange of co-repressors with co-activators 
and subsequently induces transcriptional 
activity of the target genes (see ref. [20] for 
details). Therefore, activation of LXR-regulated 
pathways using RXR agonists appeared as 
promising approach to circumvent undesirable 
effects of the currently available LXR agonists. 
Indeed, Cramer et al. (2012) reported recently 
that administration of the RXR agonist 
bexarotene to APP/PS1 mice reversed cognitive 
impairments, decreased soluble Aβ levels and, 
most strikingly, reduced Aβ plaque area for 50% 
within only 72 hours [86]. Unfortunately, none 
of the follow-up studies could replicate the 
effect of bexarotene on Aβ plaques [87-90] and 
only two out of four were able to confirm the 
effect on soluble Aβ levels [87,90], one of them 
reproducing also cognitive improvements [87]. 
However, the FDA-approved formulation of 
bexarotene, Targretin, has entered phases I and 
II clinical trials in AD patients [91], regardless of 
this inconstancy in preclinical results.
5. conclusions
Genetic deletion studies in mice have provided 
clear evidence for the role of LXR in AD-related 
pathological processes. On the other hand, a 
potential contribution of genetic variants in 
human LXR genes to the etiopathogenesis of 
AD remains controversial and further genetic 
association as well as functional studies are 
warranted. LXR directly regulate multiple 
genes involved in lipid/cholesterol homeostasis 
and immune cell function, both of which 
seem to be disturbed in AD. Outcomes of 
pharmacological studies in different in vitro 
and in vivo models of AD strongly suggest that 
activation of LXR-regulated pathways might be 
a promising approach to modulate or even cure 
AD (Figure  1). Most of this research has been 
done in mice or mouse-derived cells, with only 
occasional exceptions [e.g. 47-49,69]. It has been 
observed that some aspects of LXR physiology 
differ between humans and rodents [92,93]. In 
order to fully understand effects of LXR agonists 
and modulators on AD pathogenesis, further 
studies are needed, particularly in experimental 
models more relevant to human physiology.
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